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MTHRF in type 2 diabetic adults
Avaliação da homocisteína plasmática de acordo com o polimorfismo 
C677T e A1298C da enzima MTHRF em adultos diabéticos tipo 2
Adriana Lima Mello1, Selma Freire de Carvalho da Cunha2, 
Maria Cristina Foss-Freitas3, Helio Vannucchi2
ABSTRACT 
Objective: To determine plasma homocysteine levels during fasting and after methionine overload, 
and to correlate homocysteinemia according to methylenetetrahydrofolate reductase (MTHFR) poly-
morphism in type 2 diabetic adults. Subjects and methods: The study included 50 type 2 diabetic 
adults (DM group) and 52 healthy subjects (Control group). Anthropometric data, and information 
on food intake, serum levels of vitamin B12, folic acid and plasma homocysteine were obtained. The 
identification of C677T and A1298C polymorphisms was carried out in the MTHFR gene. Results: 
There was no significant difference in homocysteinemia between the two groups, and hyperho-
mocysteinemia during fasting occurred in 40% of the diabetic patients and in 23% of the controls. 
For the same polymorphism, there was not any significant difference in homocysteine between 
the groups. In the Control group, homocysteinemia was greater in those subjects with C677T and 
A1298C polymorphisms. Among diabetic subjects, those with the A1298C polymorphism had lower 
levels of homocysteine compared with individuals with C677T polymorphism. Conclusion: The 
MTHFR polymorphism (C677T and A1298C) resulted in different outcomes regarding homocystein-
emia among individuals of each group (diabetic and control). These data suggest that metabolic fac-
tors inherent to diabetes influence homocysteine metabolism. Arq Bras Endocrinol Metab. 2012;56(7):429-34
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RESUMO 
Objetivo: Determinar os níveis plasmáticos de homocisteína de jejum e após sobrecarga de me-
tionina e correlacionar a homocisteinemia com o polimorfismo C677T e A1298C da metilenote-
tra-hidrofolato redutase (MTHFR) em diabéticos tipo 2. Sujeitos e métodos: O estudo incluiu 50 
adultos diabéticos tipo 2 (Grupo DM) e 52 indivíduos saudáveis (Grupo controle). Obtiveram-se 
os dados antropométricos, de ingestão alimentar, níveis séricos de vitamina B12, ácido fólico e 
homocisteína plasmática. Os polimorfismos C677T e A1298C foram identificados no gene da en-
zima MTHFR. Resultados: Não houve diferença na homocisteinemia entre os grupos, embora a 
hiper-homocisteinemia de jejum tenha ocorrido em 40% dos diabéticos e 23% dos controles. Para 
o mesmo polimorfismo, não houve diferenças na homocisteinemia entre os grupos de estudo. 
Nos controles, a homocisteína foi maior entre aqueles com polimorfismos C677T e A1298C. Os 
diabéticos com polimorfismo A1298C apresentaram menores níveis de homocisteína quando 
comparados àqueles com polimorfismo C677T. Conclusão: Os polimorfismos da MTHFR (C677T 
e A1298C) resultaram em resposta distinta na homocisteinemia entre os indivíduos dentro de 
cada grupo (diabéticos e controles). Os dados sugerem que fatores metabólicos inerentes ao es-
tado diabético influenciam o metabolismo da homocisteína. Arq Bras Endocrinol Metab. 2012;56(7):429-34
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INTRODUCTION
Cardiovascular involvement in diabetes has been attributed to fluctuations in glycemic levels and 
to risk factors, such as systemic arterial hypertension, 
smoking, obesity, insulin resistance, microalbuminuria, 
and dyslipidemia (1). In addition, elevation in plasma 
homocysteine levels has been considered an indepen-
dent cardiovascular risk factor, contributing to increased 
morbidity and mortality among diabetic patients (2). 
Endothelial injury secondary to hyperhomocysteinemia 
may be due to greater production of reactive oxygen 
species, to platelet activation, to smooth muscle cell 
proliferation, and to thrombotic phenomena (3,4). 
Several factors have been pointed out as determinants 
of hyperhomocysteinemia, such as folate, vitamin B6 and 
vitamin B12 deficiencies (5), impaired renal function (6), 
hypothyroidism (7), as well as genetic predisposition. Hy­
perhomocysteinemia has been attributed to genetic defects 
of the remethylation pathway responsible for the conversion 
of homocysteine to methionine, or of the transsulfuration 
pathway, which converts homocysteine to cysteine. The ab­
normal increase in homocysteine after methionine overload 
indicates disorders of the transsulfuration pathway (8).
The main genetic causes of hyperhomocysteinemia are 
mutations resulting in deficiency of the enzymatic activi­
ty of methylenetetrahydrofolate reductase (MTHFR), of 
cystathionine beta­synthase (CBS) and, to a lesser extent, 
of methionine synthase (MS) (9,10). C677T and A1298C 
gene polymorphisms of enzyme MTHFR interfere with the 
remethylation pathway and cause an increase plasma ho­
mocysteine during fasting (11,12).
The aim of this study was to assess plasma levels of ho­
mocysteine under fasting and after methionine overload, 
besides analyzing hyperhomocysteinemia during fasting, 
according to enzyme MTHFR gene polymorphism in type 
2 diabetes patients and control subjects. 
MATERIALS AND METHODS
Subjects
This study was conducted on 50 type 2 diabetes pa-
tients (DM group) followed up at the diabetes outpa-
tient clinic of a university hospital. Mean patient age 
was 48.2 ± 7.6 years, 70% were females and 62% had 
been diagnosed with diabetes 10 years or less before 
the study. The Control group consisted of 52 healthy 
individuals aged 38.9 ± 8.6 years, 57.7% females, with 
fasting glycemia within the normal range. Subjects who 
showed active infectious diseases, acute inflammatory 
disease, and renal insufficiency, were pregnant and nur-
sing, and individuals with mental, hearing and visual di-
sabilities, smokers, alcohol drinkers and subjects taking 
vitamin supplements were excluded from the study. 
The protocol was approved by the ethics committee of 
the institution. All subjects were informed of the pur-
pose of the study and gave their informed consent to 
take part in the investigation. 
Study design
All subjects underwent a nutritional, physical and labo-
ratory examination to rule out any underlying disease. 
Fasting blood samples were used to determine basal 
plasma homocysteine levels; glucose, creatinine, folate, 
and vitamin B12 serum levels; and to identify C677T and 
A1298C MTHFR gene polymorphism. For the deter-
mination of the serum vitamin levels, samples were kept 
away from light. Plasma and serum samples were placed 
on ice and transported to the laboratory within 30 min 
of collection. Blood was centrifuged at 4ºC (3,000 rpm, 
10 min), frozen and stored at -70ºC until analysis. 
Right after collection of the fasting blood sample, me­
thionine (MERCK®) was administered orally (100 mg/kg 
body weight), diluted in 250 mL of mate tea (13). A new 
blood sample was collected 4 hours later for the determina­
tion of plasma homocysteine levels after methionine over­
load. After the first blood collection, volunteers ate a stan­
dardized methionine­poor breakfast and lunch, adding up 
a total of 0.9 g methionine (14).
Nutritional and clinical evaluation
Nutritional status was assessed by measuring weight, 
height and abdominal circumference using previously 
described techniques. Body mass index (BMI) was cal-
culated as weight/height2 (kg/m2) and subjects were 
considered to be overweight or obese when BMI was 
≥ 25 kg/m2. Normal values for waist circumference 
measurements were 102 cm for men and 88 cm for 
women (15). The composition of the habitual diet was 
based upon the Semi-Quantitative Food Frequency 
Questionnaire. Folate, vitamin B6 and B12 intakes were 
determined over the six-month period preceding the 
study, by means the software NutWin Profissional® 1.5 
(Universidade Federal de São Paulo – Unifesp, São 
Paulo, Brazil). Glycemia was determined by the ortho-
toluidine method using a LABTEST® kit, with normal 
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values below 100 mL/dL. Serum creatinine was deter-
mined by colorimetry using a LABTEST® kit, with nor-
mal values below 1.5 mg/dL. Folate (reference range 
3.0-17.0 ng/mL) and vitamin B12 (reference range 
174.0-879.0 pg/mL) were measured by chemolumi-
nescence in a competitive solid phase enzymatic assay 
using the IMMULITE 2000 kit (DPC® MEDLAB). 
Homocysteine assay
Plasma homocysteine was measured by automated 
high performance liquid chromatography (HPLC) 
with fluorescence detection (SHIMADZU, LC 9A) 
and a reverse-phase C18 column, using a specific kit 
(IMMUNDIAGNOSTIK®, Germany). Fasting plasma 
homocysteine levels of 15.0 mmol/L or less were con-
sidered normal (16). The upper normal limits for ho-
mocysteine after methionine overload were based on 
the sum of the mean + 2 standard deviations of the 
value detected in the control group (4), so that values 
lower than 44.2 mmol/L were considered normal.
Analysis of MTHFR gene polymorphism
Genomic DNA was extracted from peripheral blood 
leukocytes using the modified salting-out technique 
described by Miller, Dykes and Polesky (1988) (17). 
Genomic DNA segments were amplified by PCR. To 
determine the amplification of PCR products, 1% aga-
rose gel (A-2790, Sigma) electrophoresis was perfor-
med using Tris-borate EDTA buffer and ethidium bro-
mide staining. The amplified fragments were analyzed 
by restriction fragment length polymorphism (RFLP) 
(18). The C677T and A1298C polymorphisms were 
analyzed in the gene that encodes the enzyme MTHFR. 
C677T mutation was detected by amplification of the 
sequence corresponding to the polymorphic region of 
exon 4 flanked by the oligonucleotide (12), followed by 
digestion with the restriction enzyme Hinf I (Prome-
ga®). A1298C mutation was determined by amplifying 
the polymorphic region in exon 7 and by digesting the 
product with the restriction enzyme Mbo II (BioLab®). 
Statistical analysis
Data were analyzed statistically using the Statistical 
Analyses System (SAS) software version 9.0 (SAS Insti-
tute, Cary, NC). In the nutritional evaluation, categori-
cal variables were compared by the chi-square test and 
are presented as proportions. We used Student t-test or 
Mann-Whitney test, according to normality of the va-
riables. Results are presented as mean ± SD (variables 
with normal distribution) or as median and range (va-
riables with non-normal distribution). The associations 
between plasma homocysteine concentrations and poly-
morphism were tested using linear regression models. In 
order to satisfy the assumptions of the adjusted model, 
logarithmic transformation of the respective response va-
riables was necessary. The model was adjusted according 
to age and gender. These results are reported as geome-
tric means with 95% confidence interval (95% CI). The 
level of significance was set at p ≤ 0.05 for all analyses.
RESULTS
Nutritional and clinical evaluation 
Compared with healthy control subjects, patients of 
DM group had a higher prevalence of BMI ≥ 25 kg/m2 
and abdominal circumference exceeding normal values 
(Table 1). Folate, vitamin B6 and B12 intakes were simi-
lar in both groups. Although there was a significant dif-
ference in serum creatinine, folic acid and vitamin B12 
between groups, all volunteers were within the normal 
range regarding these parameters. Even though the 
DM group was being regularly followed up in the out-
patient clinic, their glycemic levels were not properly 
controlled at the time of the evaluation.
Plasma homocysteine under basal conditions and 
after a methionine overload 
There was no significant difference between DM and con-
trol subjects in fasting homocysteinemia or after methio-
nine overload (Table 1). Despite the tendency to wards 
higher percentage of individuals with increased fasting 
plasma homocysteine levels among the diabetic patients 
(40.0% vs. 23.1%, p = 0.06), hyperhomocysteinemia after 
the methionine overload was similar in the two groups. 
Homocysteine according to MTHFR gene 
polymorphisms
Heterozygote and homozygote C677T mutation fre-
quencies were 49.0% and 13.7% in diabetic patients, 
versus 48.1% and 7.4% in control subjects, in Hardy-
Weinberg equilibrium (p = NS between groups). The 
heterozygote and homozygote A1298C mutation fre-
quencies were 27.5% and 5.9% in diabetic patients, ver-
sus 44.4% and 5.6% in control subjects, respectively (p 
= NS between groups).
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Table 1. General characterization of individuals with diabetes mellitus 
(DM) and controls subjects 
Variables DM Group(n = 50)
Control Group
(n = 52)
Age (years)* 48.2 ± 7.6 38.9 ± 8.6
Gender (female/male ratio) 35/15 30/22
BMI (kg/m2)* 29.5 (22.5-51.7) 26.4 (17.9-40.6)
BMI ≥ 25 kg/m2 [n (%)]* 44 (88.0) 32 (61.5)
Increased abdominal 
circumference [n (%)]*
39 (78.0) 21 (40.4)
Usual nutrient intake 
 Folate (mg/day) 193.5 ± 83.2 181.9 ± 63.9
 Vitamin B
6
 (mg/day) 1.3 ± 0.5 1.5 ± 0.5
 Vitamin B
12
 (mg/day) 3.9 (0.6-31.4) 5.4 (1.3-31.0)
Fasting blood glucose (mg/dL)* 158.3 (53.0-404.0) 79.6 (62.9-113.3)
Serum creatinine (mg/dL)* 1.0 ± 0.2 0.9 ± 0.2
Serum folate (ng/mL)* 9.3 (4.0-16.7) 10.8 (5.7-20.4)
Serum vitamin B
12
 (pg/mL)* 409.5 (211.0-1200.0) 334.0 (179.0-887.0)
Homocysteine preload (μmol/L) 12.8 (3.7-33.3) 11.9 (6.7-37.1)
Homocysteine afterload (μmol/L) 34.0 (11.4-30.9) 30.1 (13.1-84.0)
Number with 
hyperhomocysteinemia (%)
 Preload > 15.0 μmol/L 40.0 23.1
 Afterload > 44.2 μmol/L 24.0 13.5
* p < 0.05; mean ± SD for variables with normal distribution; median (minimum-maximum) for 
variables with non-normal distribution.
The distribution of homocysteinemia under fasting 
conditions according to enzyme MTHFR gene polymor­
phisms in the two groups is shown in Table 2. Consider­
ing the same polymorphism, there was no difference in 
plasma homocysteine values between diabetic patients and 
healthy control subjects. However, plasma homocysteine 
concentrations were significantly lower in the DM group 
(p = 0.04) in the presence of A1298C polymorphism than 
in the presence of C677T gene polymorphism. In the Con­
trol group, homocysteine levels were higher among indivi­
duals with polymorphisms (alone or in combination) than 
among individuals without polymorphisms. 
Table 2. Geometric means and confidence intervals (95% CI) of fasting plasma homocysteine levels (mmol/L) according to MTHFR genotype in the 
diabetes mellitus (DM) and control groups 
MTHFR polymorphisms
Plasma homocysteine level (mmol/L)#
n DM Group n Control Group
Absence C677T or A1298C 9 12.3 (9.6-15.8) 9 8.9 (7.0-11.5)
C677T (alone) 25 14.4 (12.3-16.9) 18 11.5 (9.6-13.7)b
A1298C (alone) 10 10.4 (8.2-13.1)a 13 13.6 (10.9-16.8)c
C677T + A1298C (in combination) 6 15.0 (11.1-20.4) 12 12.5 (10.1-15.4)d
# After adjustment for age and gender.
a p ≤ 0.05 between A1298C vs. C677T polymorphisms in the DM group; b p ≤ 0.05 between C677T polymorphism vs. no polymorphisms in the Control group; c p ≤ 0.05 between A1298C 
polymorphism vs. no polymorphisms in the Control group; d p ≤ 0.05 between C77T+A1298C polymorphism vs. no polymorphisms in the Control group.
DISCUSSION 
In this study, there was a trend towards a greater num-
ber of subjects presenting fasting hyperhomocysteine-
mia in the DM group than in the Control group. There 
was no difference in plasma homocysteine levels be-
tween diabetic and control subjects according to each 
MTHFR gene polymorphism. On the other hand, ho-
mocysteine levels varied among the different polymor-
phisms within each study group. Plasma homocysteine 
concentration was lower among control individuals 
with no polymorphisms than among individuals with 
separate or associated polymorphisms. Among diabetic 
patients, homocysteine levels were lower in the presen-
ce of A1298C polymorphism than in the presence of 
C677T gene polymorphism. 
Our results are in agreement with data reported in the 
literature showing that A1298C polymorphism alone is 
not associated with hyperhomocysteinemia (19,20). It has 
been shown that the effect of this mutation is more relevant 
when serum folate levels are low (21), or when the muta­
tion is associated with C677T polymorphism (22). When 
compared with subjects with A1298C polymorphism, ho­
mozygotes with C677T polymorphism presented greater 
reduction of MTHFR activity, lower plasma folate levels, 
and more marked hyperhomocysteinemia (20,22,23). 
Lack of correlation between C677T mutation and the 
homocysteine levels suggest that environmental and other 
genetic factors seem to have greater influence on homo­
cysteine levels in patients with coronary atherosclerotic 
disease (24). Mazza and cols. (25) described that, in the 
absence of nephropathy, fasting homocysteine levels were 
not related to C677T MTHFR genotype, but were inversely 
related to glycemia. 
Reduced peripheral resistance to insulin has been con­
sidered responsible for lower plasma homocysteine lev­
els in the initial phases of experimental diabetes (26,27), 
due to increased transsulfuration (28). On the other hand, 
Homocysteine and MTHRF polymorphism in DM
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variations in serum homocysteine levels were not related 
with insulin, proinsulin, and insulin sensitivity among the 
Parkatêjê Indians (29). Hyperglycemia has a hyperosmolar 
effect that enhances glomerular filtration and may increase 
urinary excretion of homocysteine (30). This mechanism 
may have been responsible for the similarity between the 
DM and Control groups regarding homocysteinemia me­
dians in this study. 
It is possible that the small sample size limited analysis 
to MTHFR gene polymorphisms. Epidemiological studies 
of genetic polymorphism require large samples, especially 
for the evaluation of hyperhomocysteinemia as a risk factor 
for chronic complications (2,7,10). On the other hand, even 
when conducted on a reduced number of patients, clinical 
studies can point out changes in the metabolic pathways of 
homocysteine (4,28). The absence of data related to serum 
concentrations of vitamin B6 and genetic polymorphisms 
of other enzymes involved in homocysteine metabolism, 
especially those of the transsulfuration pathway, are some 
of the limitations of the present study. 
In conclusion, this study shows that homocysteine plas­
ma levels (before or after methionine load) were similar 
between diabetic patients and healthy controls, although 
hyperhomocysteinemia was more common among the 
diabetic patients. The presence of polymorphisms in the 
MTHFR genes resulted in increased homocysteine plasma 
levels among control subjects. Among diabetic patients, 
the only finding was that the A1298C polymorphism re­
sulted in lower homocysteinemia when compared with 
C677T. The different outcomes between diabetic patients 
and control individuals suggest that the diabetic metabolic 
environment may be involved in the metabolism of homo­
cysteine, regardless of MTHFR polymorphisms.
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